Polycaprolactone Efficient for Nasolabial Fold Treatment

This article originally appeared here.
Share this content:
Polycaprolactone Efficient for Nasolabial Fold Treatment
Polycaprolactone Efficient for Nasolabial Fold Treatment

(HealthDay News) -- For patients with nasolabial folds (NLFs), treatment with a novel biostimulatory polycaprolactone (PCL)-based dermal filler is associated with improved long-lasting efficacy compared with nonanimal stabilized hyaluronic acid (NASHA)-based fillers. This finding was published online Jan. 6 in the Journal of Cosmetic Dermatology.

Hassan Galadari, M.D., from the United Arab Emirates University in Al Ain, and colleagues conducted a randomized split-face study to compare a novel PCL-based dermal filler with a NASHA-based dermal filler in 40 patients. The authors compared the safety, efficacy, and duration of cosmetic correction for the treatment of NLFs.

The researchers found that compared with NAHSA-based filler, NLFs treated with the PCL-based dermal filler showed statistically significant improvements on the Wrinkle Severity Rating Scale and greater improvements on the Global Aesthetic Improvement Scale at six, nine, and 12 months post-treatment. The products were found to be equivalent in terms of safety and tolerability.

"Our results suggest that PCL-based dermal fillers offer longer-lasting performance over NASHA-based dermal fillers in NLFs treatment," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

WHO: Vaccine Hesitancy a Major Global Health Threat

WHO: Vaccine Hesitancy a Major Global Health Threat

Percentage of U.S. children 19 to 35 months who have not been vaccinated has quadrupled since 2001

FDA Down to 5 Weeks of Funding to Review New Drug Applications

FDA Down to 5 Weeks of Funding to ...

Agency cannot accept new fees or applications until the shutdown is over

FDA Approves First Generic Version of Epilepsy Drug Sabril

FDA Approves First Generic Version of Epilepsy Drug ...

Generic equivalents held to same vigorous manufacturing standards as brand-name drugs

is free, fast, and customized just for you!




Already a member?

Sign In Now »